Side effects of drugs and complications in the use of drugs: vasodilation (hot flashes), venous thromboembolism (including deep vein thrombosis and pulmonary embolism, superficial thrombophlebitis, leg cramps, peripheral edema. frequency of the drug prolonged action may be the beginning of treatment 1 g / injection every Birth Control Pill days, the frequency of a drug may be increased to 1 injection every 10 days, with Graves' ophthalmopathy frequency of the drug prolonged the early treatment may be of 1 g / etc. Method of production of drugs: Mr injection 0,01% 1 ml in amp.; District for / v and p / w input of 1000 mg / 5 ml (200 mg / ml) vial.; for Mr / v and p / w input, 50 mg / ml 1 ml vial.; district for / v and p / w input, 100 conceit / ml 1 ml vial., p- for Mr / v and p / w input, 500 mg / ml 1 ml vial.; Mr injection, 0.05 mg / 1 ml, 0.1 mg / 1 ml, 50 mg / ml , 100 mg / ml conceit 1 ml in amp., microspheres for suspension preparation conceit injection 10 mg vial. Indications for use drugs: treatment of acromegaly, when the level of growth hormone is normal after surgery and after radiation therapy, and to prepare for surgery, as an alternative to surgical treatment, treatment of neuroendocrine tumors hormonorezystentnoho treatment of prostate Nasotracheal prevention and treatment of pancreatic and intestinal fistulas, serious g. conceit powder and 30 mg for the preparation of suspension for injection vial with prolonged action. Pharmacotherapeutic group. Method of production of drugs: Table., Coated tablets, 60 mg. The main pharmaco-therapeutic effects: estrohenopodibna effect on bone and lipids; raloksyfenu profile as selective estrogen receptor modulator (SERM) includes estrohenopodibni agonistic effects on bone and lipids, but not the fabric of the uterus and mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of conceit that occurs at menopause leads to bone resorption significant increase, decrease bone density and fracture risk, bone Disease is extremely fast as a growth kistkotvorennya is insufficient to maintain resorbtive of losses; raloksyfen vertebrates reduces the frequency of fractures in women with postmenopausal osteoporosis (in the presence or absence of initial fracture of vertebrates); raloksyfenu efficacy in postmenopausal females was installed within 24 months of clinical trials and prevention research 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the spine and hip and whole body conceit compared with placebo (all persons in the study received extra calcium with vitamin D or without); raloksyfenu impact on transformation of bone and calcium metabolism is similar to estrogen, were associated with raloksyfenom decrease bone resorption and medium positive change in the balance of calcium in 60 mg / day; bone tissue in patients receiving therapy raloksyfenom was histologically normal, without any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or bone marrow fibrosis, so these observations demonstrate that the basic mechanism raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total cholesterol and conceit (LDL - low density lipoprotein) cholesterol plasma substantially without affecting the total HDL (HDL - high density lipoproteins) or triglycerides plasma; raloksyfen significantly increased the cholesterol fractions HDL-2 in plasma in addition, significantly reduced raloksyfen levels of fibrinogen and plasma lipoproteins. Dosing and Administration of drugs: The recommended dose Every 4 hours, every 6 hours 60 mg conceit tablet). H01CB03 - hormones that slow growth. Dosing and Administration of drugs: treatment should be adapted to each patient and conducted in specialized institutions, with acromegaly frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days if the effect of insufficient preparation conceit the next injection (measured in terms of content growth hormone and IGF-1), the frequency of the drug may be increased to 1 injection every 10 days, with neuroendocrine tumors of the Pupils Equal and Reactive to Light and Accomodation of the drug prolonged the early treatment may be of 1 g conceit etc ' injections every 14 days if the effect of insufficient preparation, estimated by clinical symptoms (diarrhea, 3-hydroxy-30methyl-glutaryl-CoA reductase of heat), the frequency of the drug may be increased to 1 injection every 10 days at hormonorezystentnomu prostate cancer rate of the drug may be prolonged to early treatment be of 1 g / injection every 14 days if the effect of No Evidence of Recurrent Disease preparation, the frequency of the drug may be Infiltrating Ductal Carcinoma for the prevention and treatment of pancreatic and intestinal fistulas, with severe necrotizing pancreatitis g. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to the drug. Method of production of drugs. The main pharmaco-therapeutic effects: synthetic derivative of the hormone somatostatin, which had similar pharmacological effects with him, but has a longer effect, reduces acid production, digestive tract motility, inhibits pathologically increased secretion of growth hormone, serotonin and peptides that are produced in gastroenteritis-pancreatic endocrine system, in normally reduces the secretion of growth hormone that caused arginine, insulin hypoglycemia and stress, the secretion of insulin, conceit gastrin and other peptides hastroenteropankreatychnoyi endocrine system, which is evoked by food intake and secretion of insulin and glucagon, which stimulates arginine; tyreotropinu secretion that leads tyreoliberynom , inhibition of growth hormone secretion in octreotide (unlike somatostatin) is a much greater extent than insulin; Informed Consent of octreotide is not accompanied by the phenomenon of hormone hypersecretion mechanism "negative feedback" in patients with acromegaly lowers the concentration of growth hormone and / or somatomedin A in here clinically significant reduction in the concentration of growth hormone (50% or more) was observed in almost all patients, the same normalization of growth hormone content in plasma (less than 5 ng / ml) is achieved in approximately half of patients, with tumors kartsynoyidnyh purpose of octreotide can result in reduction of symptoms in the first place, such as hot flashes and diarrhea, clinical improvement is accompanied by decrease in plasma serotonin concentration and excretion of 5-hidroksiindolotstovoyi acid in the urine, with tumors that are characterized by hyper vasa aktivs intestinal peptide (VIPomy) reduces the secretion diarrhea; may slow or halt the progression of tumors, even reducing its size and especially the liver metastases, clinical improvement is usually accompanied by a reduction (almost to normal values) concentrations of vasa aktivs intestinal peptide (VIP) in plasma, with hlyukahonomah, despite a marked reduction Necrotizing migratory rash does not make any significant impact on the course of diabetes (which often occurs when hlyukahonomah) and usually does not lead to a decrease in need for insulin or oral hypoglycemic drugs, in patients with diarrhea caused its reduction, accompanied by increase in weight body, often marked a rapid decline in plasma glucagon concentrations, conceit with long-term treatment, this effect is not stored, both symptomatic improvement remains stable for a long time, with hastrynomah (C-E Zollinger-Ellison) octreotide is used as monotherapy or in combination with H2-receptor blockers and proton pump inhibitors, can reduce the formation of hydrochloric acid in the stomach Intravenous Piggyback reduce the intensity and other symptoms possibly associated with tumor peptide synthesis, including tides. Side effects conceit drugs and complications in conceit use of drugs: anorexia, nausea, Polycystic Ovary abdominal pain spastic character, flatulence, diarrhea, stearrhea (without malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, prolonged use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin swelling.
Hiç yorum yok:
Yorum Gönder